Final-Program-ATS-2023-AP.vp

244

TUESDAY • MAY 23

P530 Patient and Physician Assessments of Clinical Status: A Mixed Methods Study of Interstitial Lung Disease/ A. Grant-Orser, Calgary, Canada P531 Bronchoalveolar Lavage Fluid and Radiographic Patterns in Patients With Fibrotic Interstitial Lung Disease/ A. Grant-Orser, Calgary, Canada P532 Whether Subspecialty Clinic Improves Screening for Causes of Interstitial Lung Disease/ S.F. Enam, Basildon, United Kingdom P533 Implementation of an Interstitial Lung Abnormality Clinic and Multidisciplinary Discussion/ K.C. Selvan, Chicago, IL P534 Exposure History and Autoimmune Serologic Profiles of Patients With Interstitial Lung Abnormalities/ K.C. Selvan, Chicago, IL P535 Prevalence of Environmental Antigens and Immunoglobulin Seropositivity in Fibrotic Hypersensitivity Pneumonitis/ C. Christian, Chicago, IL P536 Reporting of Exposures by Patients With Interstitial Lung Disease During an Unstructured Clinician Interview or on a Questionnaire/ L. Yun, Nashville, TN P537 Differences in Baseline Characteristics and Diagnostic Confidence Over Time Between Interstitial Lung Disease Subtypes in a Pulmonary Fibrosis Foundation Registry Cohort/ D. Zhu, Charlottesville, VA P538 Machine Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease/ E.D. Farrand, San Francisco, CA P539 Differences in Exertional Oxygen Needs in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD): Use of a Ramped Protocol Treadmill Exercise Test/ K. Clark, Pittsburgh, PA P540 Recovery Rate From Exertional Desaturation Is Associated With Disease Severity in Patients With Fibrotic Interstitial Lung Disease/ A. Tyker, Hamilton, ON P541 Characteristics of Arterial Blood Gas in Patients With Fibrotic Interstitial Lung Disease/ M. Donaldson, Vancouver, Canada P542 Introduction of Home Spirometry in Tracking Disease Progression in Patients With IPF: Baseline Data From the Prospective Treatment Efficacy in IPF Using Genotype for NAC Selection (PRECISIONS) Clinical Trial/ A. Podolanczuk, New York, NY P543 Home Spirometry Monitoring in Patients With Interstitial Lung Disease/ W.L. Ng, Dublin, Ireland P544 Implementation and Performance of a Standardized 6-minute Walk Test in Idiopathic Pulmonary Fibrosis: Results From the Isabela Studies/ S.D. Nathan, Falls Church, VA

P518 Metastatic Pulmonary Calcification: An Exceptional Complication Associated With End-stage Renal Disease Mimicking Transbronchial Infection/ N. Jirawat, Pathum Wan, Bangkok, Thailand P519 Pneumothorax As An Unexpected Presentation Of Silicosis/ C. Tom, Los Angeles, CA P520 Are You Dyspneic or Is It Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia (DIPNECH)?/ J. Hitchings, Philadelphia, PA P521 Tracheobronchopathia Osteochondroplastica: A Case of an Unexpected Encounter in the Airways/ J.E. Miller, Roanoke, VA P522 Tracheobronchial Amyloidosis in a Patient With More Than 16 Years of Follow-up/ P.M. Cavalcante Neto, Sao Paulo, Brazil P523 Hemophagocytic Lymphohistiocytosis Secondary to Sarcoidosis/ V. Hegde, Kansas City, KS

CLINICAL THEMATIC POSTER SESSION

C39

CARE AND EVALUATION OF PATIENTS WITH INTERSTITIAL LUNG DISEASE

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P525 Usability of a Smartphone Application for Patients With Interstitial Lung Disease (ILD): Early Results From the Registry for Better Understanding of ILD (RE-BUILD) Pilot Study/ L.M. Glenn, Camperdown NSW, Australia P526 Development of Duke Empower: A Platform to Engage, Inform, Probe, Promote Wellness, and Foster Community Among Patients With Rare Diseases/ A.C. Swaminathan, Durham, NC P527 Perceptions of Pulmonary Fibrosis Foundation Care Center Network Providers Caring for Rural Patients With Interstitial Lung Disease/ A.M. Dedent, San Francisco, CA P528 Preferences and Attitudes Regarding a Peer Support Intervention for Individuals With Chronic Hypersensitivity Pneumonitis: A Survey of Clinicians/ N.M. Holbrook, New York, NY P529 Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Quality Improvement Initiative/ R.A. Patel, Orange, CA

ATS 2023 • Washington, DC